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Abstract Over the past few decades, advances in ven-
tricular assist device (VAD) technology have provided a
promising therapeutic strategy to treat heart failure
patients. Despite the improved performance and encour-
aging clinical outcomes of the new generation of VADs
based on rotary blood pumps (RBPs), their physiologic and
hematologic effects are controversial. Currently, clinically
available RBPs run at constant speed, which results in
limited control over cardiac workload and introduces blood
flow with reduced pulsatility into the circulation. In this
review, we first provide an update on the new challenges of
mechanical circulatory support using rotary pumps
including blood trauma, increased non-surgical bleeding
rate, limited cardiac unloading, vascular malformations,
end-organ function, and aortic valve insufficiency. Since
the non-physiologic flow characteristic of these devices is
one of the main subjects of scientific debate in the litera-
ture, we next emphasize the latest research regarding the
development of a pulsatile RBP. Finally, we offer an out-
look for future research in the field.
Keywords Ventricular assist devices  Rotary blood
pumps  Heart failure  Continuous flow  Pulsatile flow
Introduction
A ventricular assist device (VAD) is a mechanical pump
that helps to improve blood circulation in patients with a
weakened ventricle. It typically draws blood from the apex
of the left ventricle (LV) and pumps it into the circulation
through the ascending aorta (Fig. 1). DeBakey [1] intro-
duced the first successful clinical applications in the 1960s.
After three decades of improvement, in the mid-1990s,
they became an established treatment option for heart
failure patients awaiting transplant as a bridge to trans-
plantation (BTT) [2]. VADs can also provide long-term
mechanical support as destination therapy (DT) and in a
relatively small number of cases with non-ischemic etiol-
ogy lead to improved cardiac function, or so-called reverse
remodeling as a bridge to recovery. The first generation of
VADs was based on a pneumatically or electrically driven
volume displacement pump (Figs. 2a, 3). Due to the
working principle analogous to the native heart with filling
(diastole) and ejection (systole) phases, they provide
excellent hemodynamic support. Nonetheless, their appli-
cations have substantial constraints because of their large
size, invasive surgical procedure, and poor durability
for long-term mechanical support [3]. These challenges
necessitated the development of a new generation of VADs
with simple design and improved performance.
Over the past two decades, the advent of rotary blood
pumps (RBPs) as assist devices has revolutionized the field
of mechanical circulatory support due to their small size
(Fig. 2), silent operation, and long-term durability. Rotary
pumps consist of only one moving part, the rotor, and are
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divided into two main categories: (1) axial flow pumps and
(2) magnetically or hydro-dynamically levitated centrifugal
pumps (Fig. 4). On the one hand, their operating mecha-
nism makes it possible to achieve a reliable and durable
device; on the other hand, it reduces the blood flow pul-
satility owing to typical use of constant speed in clinically
available devices. Despite improvements in clinical out-
comes and advantages over pulsatile pumps, fundamental
questions persist particularly about unknown physiologic
effects of reduced arterial pulsatility in a milieu of tolerable
but persisting adverse events.
Here, we first focus on the current challenges of RBPs.
Then, we review recent attempts to develop a pulsatile
rotary pump, and finally, we offer an outlook for further
research.
Emerged concerns
Although adverse events, including surgical mortality, right
ventricular failure, neurological events, and infections, as
Fig. 1 The schematic of an implanted VAD and its components,
courtesy of Thoratec Corporation
Fig. 2 Different types of blood pumps. a HeartMate XVE (volume displacement pump), b HeartMate II (axial rotary pump), c HeartMate III
(centrifugal rotary pump), courtesy of Thoratec Corporation
Fig. 3 The schematic of a pneumatic pulsatile VAD cross-section,
courtesy of Thoratec Corporation
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with pulsatile devices, still persist for rotary pumps, in this
section, we only focus on concerns related to working
mechanism of RBPs. These include blood trauma, increased
rate of non-surgical bleeding, limited cardiac unloading,
vascular malformations, end-organ function, and aortic
valve insufficiency.
Blood trauma
Depending on the design, miniaturized RBPs might reach
rotational speeds (x) higher than 30,000 revolutions per
minute to supply enough blood flow. Upon passage through
the pump, blood cells and proteins are exposed to very
brief durations of high shear stress level of about 1,000 Pa
(unpublished data), which are possible sources of damage
to blood particles. Although the exact hematologic effects
of RBPs have not been completely investigated, elevated
shear forces play an important role in the incidence of
thromboembolism. It is widely recognized that platelets
together with a plasma protein, von Willebrand factor
(vWF), play an essential role in both thrombus formation
and hemostasis. Increased shear forces disturb the normal
distribution of vWF molecules and may result in acquired
von Willebrand syndrome. According to Sheriff et al. [4],
platelets exposed to high shear stress for a short time are
sensitized to subsequent lower values and activate at least
20-fold faster than particles under standard circulation
conditions. Platelets and white blood cells are sensitive to
mechanical stress at levels of 10 and 7.5 Pa, respectively,
whereas red blood cells are less sensitive with high level of
a few hundred Pa [5]. However, exposure time to
mechanical force is critical for the maximum shear stress
tolerable by cells. For example, 800 Pa with an exposure
duration of 1 ms has been reported as the hemolytic
threshold [6]; whereas another study shows that by
increasing the exposure time to 700 ms, hemolysis occurs
at shear stress of 255 Pa [7]. It should be noted that in
normal vascular blood flow, the maximum shear stress is
approximately 6 Pa occurring in the wall of arterioles [8].
These data show that devices designed based on only
hemolysis tests are not optimized to reduce thromboge-
nicity due to high mechanical forces.
Furthermore, elevated shear stress enhances the shed-
ding of various microparticles (MPs) from blood cells, as
well as endothelial cells into circulation. These submicron
particles, which are components of cells plasma mem-
branes and bear membrane proteins of their mother cell,
play an essential biologic role in inflammation, vascular
injury, angiogenesis, and thrombosis [9]. A recent research
study by Diehl et al. [10] demonstrates that VAD patients
have elevated levels of circulating MPs, which may con-
tribute to the occurrence of thromboembolic complications.
While MPs have important physiologic and pathologic
roles, their contributions to the side effects of RBPs remain
unexplored. Further details about hematologic effects of
RBPs are found in previous publications [11, 12].
Bleeding
Increased non-surgical bleeding, specifically in the gas-
trointestinal (GI) tract, is one the most frequent adverse
events associated with RBPs [13]. In 2005, Letsou et al.
[14] were the first to report 3 cases of GI bleeding after
implantation of the Jarvik 2000 in 21 patients. By
reviewing 101 VAD recipients (55 rotary and 46 pulsatile
pumps), Crow et al. [15] reported almost 10-fold increases
in the incidences of GI bleeding in rotary versus pulsatile
devices. Additionally, based on long-term clinical studies
performed between 2003 and 2011, there is sufficient evi-
dence to demonstrate higher rates of GI bleeding event in
patients supported with axial and centrifugal rotary pumps,
which was not the case for patients receiving pulsatile
devices [16, 17].
In an interesting study, Uriel et al. [18] tried to identify
potential mechanisms for those bleeding events and
investigated vWF multimers in rotary pump patients. They
observed a reduction in vWF multimers of 31 patients,
whereas only 18 of them (58 %) experienced bleeding.
Their finding is supported by other studies that show sig-
nificant loss of vWF multimers in RBP recipients, but only
Fig. 4 a Components of an
axial flow rotary blood pump,
b components of a centrifugal
rotary blood pump, courtesy of
Thoratec Corporation
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some patients had bleeding complications [19, 20]. A
similar problem of an acquired form of von Willebrand
syndrome with subsequent bleeding has been reported in
patients with aortic stenosis [21]. Taken together, increased
pressure inside blood vessels, high shear stress, and low
pulse pressure were suggested as potential explanations for
von Willebrand disease [15]. These findings indicate that
loss of vWF multimers alone cannot predict bleeding risk.
Although the biology and mechanism behind the bleeding
is not completely understood, its higher rate associated
with RBP recipients makes it rational to draw the conclu-
sion that (1) the high-speed rotor causes damage to blood
particles or (2) attenuated pulsatility plays an important
role. Further research is required to identify risk factors for
bleeding in these patients.
Limited cardiac unloading
A promising application of VADs besides their usage in the
BTT and DT is as a bridge to myocardial recovery [22]. It
was first reported by Levin et al. [23] in 1996, who found a
considerable functional and structural improvement in the
failing heart of a young patient after 6 months of support. It
is likely that mechanical unloading stimulates the cellular
biology of the myocardium and initiates recovery by alle-
viating the cardiac workload and relieving the biome-
chanical stress imposed on the cardiomyocytes [24].
Cardiac unloading is also associated with improvements in
matrix metalloproteinase activity, myocyte calcium han-
dling, and neurohormonal stimulation [25]. However, the
precise mechanism by which a failing heart recovers is not
completely clear.
By conducting studies on explanted human hearts, Levin
et al. [26] demonstrated that ventricular dilation because of
chronic cardiomyopathy could be largely reversed after
3–5 months of mechanical support. Their finding was
supported by Altemose et al. [27] who observed reductions
in LV chamber size and a 40 % decrease in LV mass in
eight patients. The cellular basis for these changes was
discussed by Zafeiridis et al. [28] who examined isolated
cardiac myocytes from VAD-supported and non-supported
failing hearts as well as healthy hearts. They observed that
mechanical support resulted in a 28 % reduction in myo-
cyte volume and 20 % reduction in cell length and width.
In addition, myocyte contractility and its rates of shorten-
ing and relengthening improve within 3 months of circu-
latory support [29]. These findings indicate that cardiac
workload is a major factor in pathologic cardiac hyper-
trophy and remodeling. Thus, mechanical unloading, which
is associated with reduced wall stress, leads to favorable
alterations in geometry at the organ and cellular levels of a
failing heart.
A series of clinical studies demonstrates that volume
displacement pumps are associated with greater LV
unloading in heart failure patients compared with rotary
pumps [30, 31]. This is consistent with data from animal
experiments demonstrating that pulsatile pumps provide
superior LV unloading and maintain a better physiologic
stability [32]. This limitation of RBPs arises mainly
because clinically available devices typically operate at
constant speed mode confining their operating range by
suction and regurgitation events. An excessive constant
pump speed results in ventricular collapse, and too low
speed leads to back flow of blood into the ventricle
increasing cardiac workload.
Vascular malformations
Blood vessels are compliant structures that respond to
physiologic conditions in terms of geometrical, structural,
and functional adaptations. These adaptations are mediated
in part by the vascular endothelial cells (ECs), which are
directly exposed to blood flow and associated shear stress.
The ECs respond to the biomechanical forces in terms of
molecular signaling, gene expression, and functional
changes [33]. Under normal blood flow and physiologic
conditions, the fluid-induced forces are mechanotransduced
into biochemical signals that result in vascular caliber
regulations as well as inhibition of thrombosis and
inflammation of the vessel wall. However, little is known
about the impact of alterations in flow patterns and
mechanical forces on ECs and vascular function in RBP
patients.
In a clinical study of 20 VAD patients, Amir et al. [34]
found lower endothelial function in conduit arteries and
impaired peripheral vascular reactivity, most likely owing
to reduced pulsatility. Westaby et al. [35] reported a
decrease in medial aortic thickness and medial smooth
muscle cell (SMC) number after 3 months of support with
Jarvik 2000 RBP in 7 patients. SMCs play a critical role
during atherogenesis, which is the developmental process
of atheromatous plaques and is characterized by remodel-
ing of arteries leading to accumulation of plaques. Other
clinical studies also provide enough evidence of arterio-
venous malformation highly associated with flow charac-
teristics of RBPs [14, 16]. These clinical observations are
further confirmed in animal studies where thinner aortic
and arterial walls as well as a lower volume ratio of SMCs
were claimed due to decreased pulsatility [36].
Furthermore, prolonged circulatory support using RBPs
significantly decreases vascular pulsatility, diminishes the
constrictive function of the vascular system, and increases
peripheral vascular resistance, which can augment the load
on the LV [36, 37]. As a result, decreased pulse pressure
and changes in blood flow pattern will lead to undesirable
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morphological changes of aortic and arterial walls, as well
as vascular surfaces, in particular, in locations such as the
descending thoracic aorta and distal carotid arteries.
End-organ function
As early as the 1950s, shortly after the development of
cardiopulmonary bypass, there was a substantial debate
about whether the non-pulsatile perfusion provides ade-
quate blood flow to maintain proper end-organ function
[37, 38]. These early studies together with cardiopulmo-
nary bypass experience during the last few decades suggest
that short-term non-pulsatile flow is well tolerated. After
the advent of rotary pumps, end-organ perfusion was a
great concern; thus, many investigators examined this issue
in animal models. Saito et al. [39] demonstrated that use of
RBPs for a few months maintained normal end-organ
function and reported no histologic abnormalities of the
brain, liver, and kidney. By contrast, a number of animal
experiments have shown variations in skin tissue micro-
circulation as well as microcirculation of the kidney and
liver, including retention of blood cells, expansion of the
proximal tubes, and glomerulus blood capillaries, but there
is no evidence that these histologic changes impair end-
organ function [40, 41]. What is more, the clinical rele-
vance of their outcome can be ambiguous because of the
use of healthy animals.
In humans, although insufficient data exist about the
effects of attenuated pulsatility on end-organ function
within a few years, clinical studies have shown that renal,
hepatic, and neurocognitive functions are maintained
within a normal range for durations up to 15 months
[42, 43]. The comparison of renal and hepatic functions in
patients who received a VAD as a BTT shows no major
difference between continuous and pulsatile flow devices
[44]. Regarding endocrine functions, there is no major
effect of reduced pulsatility on the hypothalamic-pituitary
end-organ system and sympathoadrenal functions [45].
Results of a study by Polska et al. [46] showed that alter-
ations in flow pulsatility had only a small influence on
blood flow in the choroid and mean flow velocities in the
ophthalmic artery. In another clinical study, Kamdar et al.
[47] compared the effects of centrifugal, axial, and pulsa-
tile VADs on end-organ function for up to 3 months; their
finding is consistent with recent reports by Slaughter [42]
and Russell et al. [48], suggesting that RBPs supply suffi-
cient end-organ perfusion, at least for a relatively short
time support. In a recent publication, Chokshi et al. [49]
provided new insight into cardiac metabolism in heart
failure patients suggesting that mechanical support
improves systemic and local metabolic derangements in
VAD patients. This may reduce myocardial levels of toxic
lipid intermediates and improve cardiac insulin signaling.
It should be noted that under most clinical conditions,
RBP patients have some degree of arterial pulsatility due to
native ventricular contractions. Further long-term studies
preferably in randomized clinical trials are crucial to assess
the effect of reduced pulsatility on pulmonary function,
microcirculatory system, neuroendocrine markers, and
cerebral blood flow, or metabolism.
Aortic valve insufficiency
One unexpected complication of mechanical circulatory
support is the development of aortic valve lesions, which
may result in commissural fusion and aortic valve insuffi-
ciency (AI). Depending on the degree of LV unloading by
VAD, the aortic valve remains partially or completely
closed, which increases the mechanical stress on the valve.
These forces affect valvular endothelial and interstitial
cells and may result in valve remodeling or pathologic
alterations [50]. In addition, changes in aortic blood flow
dynamics and myxoid degeneration of the aortic valve
were suggested to contribute to AI development and pro-
gression [51]. AI impairs the VAD function, increases the
risk of thromboembolism events, and is a great concern in
potential bridge to recovery patients. Although this com-
plication was reported during support by volume dis-
placement pumps [52], recent studies suggest that AI is
more prevalent among RBP recipients [53, 54]. Intermit-
tently lowering the pump speed, which allow opening of
the aortic valve during systole, was suggested to reduce the
risk of thrombus formation in the aortic root and prevent
leaflet fusion [55]. A better understanding of the RBP
impact and the relationship between mechanics and valve
biology will provide insights into the pathophysiology of
aortic valve disease. A recent publication by John et al.
[50] describes the basis for structural changes and discusses
different techniques of aortic valve management during
VAD support in more detail.
Towards a pulsatile rotary blood pump
As controversy remains on the long-term effects of perfu-
sion with reduced pulsatility, speed modulation of the
pump might be beneficial to restore vascular pulsatility.
Besides its effect on reducing complications potentially
tied to reduced arterial pulsatility, speed modulation of
RBPs can effectively control cardiac workload [56, 57],
which is likely important for heart recovery and device
weaning. Moreover, the introduction of pulsatile RBPs
would provide a unique opportunity for further research
and comparison. In the literature, there are few reports
describing the attempts to modulate the rotary pump’s
speed, which only focus on asynchronous speed
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modulation [58], mathematical modeling [59], and in vitro
investigation of pump speed modulation using mostly
sinusoidal waveforms [60].
Bourque et al. [61] evaluated the impact of a pulsatile
centrifugal pump on an ovine thoracic and abdominal
aortic flow and pressure. To eliminate all native cardiac
contributions to pulsatility, they replaced both ventricles
with HeartMate III blood pumps. Pulsatile flow was
achieved by sharply alternating the speed of the magneti-
cally levitated rotor of the left pump between 1,500 rpm
(diastole) and 5,500 rpm (systole) at a rate of 60 bpm and a
systolic period of 30 %. Results showed that the mean
pump-induced pulse pressure was 34 mmHg in the
ascending aorta and the maximum rate of pressure rise (dp/
dt) was between 189 and 238 mmHg/s, approaching that of
the native pulse. Ando et al. [62] studied the effect of speed
modulation of the EvaHeart RBP on myocardial perfusion
in an animal model and reported an increase in coronary
flow compared with the continuous mode. According to
Pirbodaghi et al. [56, 57], pump speed modulation syn-
chronized with the native heart can significantly influence
myocardial energy as well as volume. Their findings indi-
cate that high pump speed during diastole has a maximal
unloading effect on LV, whereas high speed during systole
increases the pulse pressure. Moreover, cardiac stroke work
in the pulsatile mode could be reduced to 72 % of that in
constant speed indicating the importance of the synchrony
between the heart and assist device on LV unloading.
Furthermore, the controllers of some commercially
available pumps (e.g. Jarvik 2000, Medos Delta stream
DP3, Heartware HVAD) vary the pump speed intermit-
tently and asynchronously to modulate the pump flow and
allow better washing. Despite these initial steps toward
pulsatile RBPs, more studies are required to explore the
concept, determine its efficiency, and assess the importance
of different prescriptive parameters.
Future considerations
While RBPs are rapidly evolving to provide destination
therapy as an alternative to heart transplantation, many
fundamental questions pertaining to their operating mech-
anisms remain to be addressed. How does the attenuated
pulsatility with RBPs affect cell–cell interactions within
the blood flow stream? What is its impact on blood cells
margination from the center of a blood vessel toward the
vascular endothelium, in particular, white blood cells that
are important in the inflammatory response? How does
elevated shear stress influence gene expression, extracel-
lular and intracellular matrices? What is the impact of
partial or complete unloading on myocardial blood flow
and metabolism? Is there a degree of pulsatility or
unloading, which may optimize myocardium recovery? In
this regard, the use of combination therapies that consist of
mechanical unloading and pharmacologic or biologic
therapies can promote recovery in a large number of
patients. It is widely known that treatment with beta-
blockers and ACE inhibitors during mechanical support
increases the probability of cardiac recovery. There is also
preliminary evidence that stem cells from percutaneous
endomyocardial biopsy specimens promote cardiac regen-
eration and improve heart function [63].
Among other issues, abdominal driveline infection is a
major concern for long-term mechanical support, as with
all VADs that have a percutaneous component [64]. Cur-
rent alternatives include a transcutaneous energy transfer
system (TETS) [65] to wirelessly power implantable
devices and skull pedestal power delivery techniques [66].
The former has poor efficiency and suffers from technical
concerns [67]; the latter requires an invasive surgery pro-
cess and is associated with a low quality of life. Thus, it is
necessary to develop more effective and reliable power
delivery systems. Recent studies [67, 68] on wireless power
transfer based on the free-range resonant electrical delivery
(FREE-D) appear promising, but more research needs to be
conducted in this area.
While platelet activation is critically correlated with
high shear stress, its aggregation is more likely to happen at
low stress levels [69], indicating that areas of stasis within
the device might contribute to thrombosis formation. Thus,
it is critical to identify low and high threshold stresses and
completely understand the fluid dynamics of the blood
inside RBPs as well as in the inflow/outflow conduits.
Furthermore, platelet adhesion and thrombus formation are
highly sensitive to exposed foreign surfaces. Despite
advances in materials with anticoagulant function, such as
heparin and hirudin, there is still no surface coating capable
of completely inhibiting thrombus formation. Currently,
the inlet and outlet elbows of VADs are textured to entrap
particles from the blood and form a biologic coating. To
eliminate the need for long-term anticoagulant therapy,
which increases the incidence of side effects, the devel-
opment of new antithrombogenic biomaterials is necessary
for the blood-contacting surfaces of the pump and cannu-
las. Owing to nonthrombogenic properties of endothelial
cells (ECs), coating with ECs can pave the way toward a
totally nonthrombogenic surface. More investigations are
needed to understand the complex molecular structures and
interactions between ECs and device surfaces.
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